Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre

Mahadevaiah, Ashwini; Doddamadaiah, Chaithra; Sadananda, K S; Nanjappa, Manjunath C

doi:10.1016/j.ijmmb.2022.03.003

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Thirthankar Deb et al [ 12 ] in a tertiary care hospital among healthcare workers in India has reported few ADRs associated with vaccination. On the other hand, Ashwini Mahadevaiah et al [ 13 ] and Deep Kamal et al [ 14 ] conducted similar studies. Those studies have shown that the first dose of vaccination shows a higher percentage of ADRs compared to the second dose of Covishield.…”

Section: Discussionmentioning

confidence: 82%

Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study

Manda¹,

Koya²,

Pallem³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 82%

Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study

Manda¹,

Koya²,

Pallem³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…On January 2021, drug regulators in India granted emergency approval for the covid vaccine co-developed by AstraZeneca and the university of Oxford. Mahadevaiah et al in their study of immunogenicity, safety, and efficacy of covishield vaccine, showed seropositivity of 69.67% which is an acceptable level of safety profile[ 83 ]. Another study on BNT162b2 mRNA vaccine phase III clinical trial consist of 43,548 individuals, among 17,411 individual 8 cases of COVID-19 positive were identified, and among 17,511 individuals 162 COVID-19-positive cases were confirmed showing 95% of vaccine efficiency [ 84 ].…”

Section: Current Scenario: Transition In Covid-19 Managementmentioning

confidence: 99%

Recent review of COVID-19 management: diagnosis, treatment and vaccination

et al. 2022

View full text Add to dashboard Cite

The idiopathic Coronavirus disease 2019 (COVID-19) pandemic outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global proportions; the World Health Organization (WHO) declared it as a public health emergency during the month of January 30, 2020. The major causes of the rise of new variants of SARS-CoV-2 are genetic mutations and recombination. Some of the variants with high infection and transmission rates are termed as variants of concern (VOCs) like currently Omicron variants. Pregnant women, aged people, and immunosuppressed and compromised patients constitute the most susceptible human population to the SARS-CoV-2 infection, especially to the new evolving VOCs. To effectively manage the pathological condition of infection, the focus should be directed towards prevention and prophylactic approach. In this narrative review, we aimed to analyze the current scenario of COVID-19 management and discuss the treatment and prevention strategies. We also focused on the complications prevalent during the COVID-19 and post-COVID period and to discuss the novel approaches developed for mitigation of the global pandemic. We have also emphasized on the COVID-19 management approaches for the special population including children, pregnant women, aged groups, and immunocompromised patients. We conclude that the advancements in therapeutic and pharmacological domains have provided opportunities to develop and design novel diagnosis, treatment, and prevention strategies. New advanced techniques such as RT-LAMP, RT-qPCR, High-Resolution Computed Tomography, etc., efficiently diagnose patients with SARS-CoV-2 infection. In the case of treatment options, new drugs like paxlovid, combinations of β-lactum drugs and molnupiravir are found to be effective against even the new emerging variants. In addition, vaccination is an essential approach to prevent the infection or to reduce its severity. Vaccines for against COVID-19 from Comirnaty by Pfizer-BioNTech, SpikeVax by Moderna, and Vaxzevria by Oxford-AstraZeneca are approved and used widely. Similarly, numerous vaccines have been developed with different percentages of effectiveness against VOCs. New developments like nanotechnology and AI can be beneficial in providing an efficient and reliable solution for the suppression of SARS-CoV-2. Public health concerns can be efficiently treated by a unified scientific approach, public engagement, and better diagnosis.

show abstract

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread all over the world and becoming a novel worldwide health threat [ 1 , 2 ]. As of April 21, 2022, there have been 505,035,185 confirmed cases of SARS-CoV-2, including 6,210,719 deaths, officially announced to WHO.…”

Section: Introductionmentioning

confidence: 99%

Sputnik V vaccine-related complications and its impression on inflammatory biomarkers in healthcare providers

Akrami¹,

Hosamirudsari²,

Faraji³

et al. 2023

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre

Cited by 3 publications

References 11 publications

Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study

Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study

Recent review of COVID-19 management: diagnosis, treatment and vaccination

Sputnik V vaccine-related complications and its impression on inflammatory biomarkers in healthcare providers

Contact Info

Product

Resources

About